Athenex Inc (NASDAQ:ATNX) has received a consensus rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $20.67.
A number of research analysts recently issued reports on ATNX shares. SunTrust Banks initiated coverage on shares of Athenex in a report on Friday, March 29th. They issued a “buy” rating and a $20.00 price objective for the company. BidaskClub raised shares of Athenex from a “sell” rating to a “hold” rating in a report on Tuesday, February 5th. Finally, Royal Bank of Canada restated an “outperform” rating on shares of Athenex in a research report on Tuesday, March 12th.
In other Athenex news, Director Sheldon Trainor-Degirolamo sold 45,915 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $11.77, for a total transaction of $540,419.55. Following the completion of the sale, the director now owns 4,000 shares of the company’s stock, valued at approximately $47,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Johnson Yiu Nam Lau bought 12,000 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were purchased at an average cost of $11.77 per share, with a total value of $141,240.00. Following the transaction, the chief executive officer now directly owns 2,932,236 shares in the company, valued at approximately $34,512,417.72. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 57,500 shares of company stock worth $696,090 and have sold 132,240 shares worth $1,559,044. 29.50% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the business. Private Advisor Group LLC lifted its stake in shares of Athenex by 6.2% in the 4th quarter. Private Advisor Group LLC now owns 17,091 shares of the company’s stock valued at $217,000 after purchasing an additional 991 shares during the period. KCS Wealth Advisory grew its stake in Athenex by 8.9% during the fourth quarter. KCS Wealth Advisory now owns 12,182 shares of the company’s stock worth $155,000 after purchasing an additional 1,000 shares during the period. Squarepoint Ops LLC increased its holdings in Athenex by 2.2% in the fourth quarter. Squarepoint Ops LLC now owns 69,720 shares of the company’s stock worth $885,000 after purchasing an additional 1,494 shares in the last quarter. Teachers Advisors LLC increased its holdings in Athenex by 4.5% in the third quarter. Teachers Advisors LLC now owns 83,771 shares of the company’s stock worth $1,302,000 after purchasing an additional 3,585 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Athenex by 2.4% in the fourth quarter. Bank of New York Mellon Corp now owns 168,870 shares of the company’s stock valued at $2,143,000 after buying an additional 3,908 shares during the period. Hedge funds and other institutional investors own 31.75% of the company’s stock.
ATNX traded up $0.26 on Friday, reaching $11.70. The stock had a trading volume of 443,042 shares, compared to its average volume of 281,735. Athenex has a fifty-two week low of $9.83 and a fifty-two week high of $20.90. The company has a quick ratio of 2.75, a current ratio of 3.31 and a debt-to-equity ratio of 0.36. The stock has a market cap of $784.13 million, a PE ratio of -8.13 and a beta of 0.21.
Athenex (NASDAQ:ATNX) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.21). The firm had revenue of $21.27 million for the quarter. Athenex had a negative net margin of 131.81% and a negative return on equity of 66.23%. On average, equities research analysts expect that Athenex will post -1.75 EPS for the current year.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Further Reading: What are popular green investing opportunities?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.